Anemia drugs slow tumor growth and provide double benefit for cancer patients

According to a new study by Finnish scientists, drugs to treat anemia may also have an anti-cancer effect. Researchers from the University of Oulu and the University of Eastern Finland have found that HIF-PHI class drugs used for chronic kidney disease can not only stimulate the production of red blood cells, but also slow down the growth of tumor cells.

Typically, these drugs work by stabilizing proteins that help cells adapt to a lack of oxygen. However, scientists have found that the drugs affect cell growth and blood vessel formation even without the participation of these oxygen-sensing proteins.

According to scientists, the results came as a surprise to the team. Instead of the expected effect only through the “oxygen” mechanism, the drugs demonstrated the ability to suppress cell growth and interfere with the formation of new blood vessels that tumors need to develop. The authors of the work believe that the discovery may be especially important for cancer patients, who often suffer from anemia due to the tumor or chemotherapy. In the future, such drugs may simultaneously help cope with both anemia and tumor growth.

The researchers are now looking for clinical partners to conduct trials on patients. Scientists emphasize that the results obtained have so far been confirmed only in laboratory conditions and require further testing in the clinic.

By Editor

One thought on “Anemia drugs slow tumor growth and provide double benefit for cancer patients”

Leave a Reply